Study of the Effects of Intravenous Exenatide on Cardiac Repolarization

PHASE1CompletedINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions
Healthy Adult Male and Female Volunteers
Interventions
DRUG

Exenatide

6 hour IV infusion (double infusion of 0.1250 mcg/kg/hour for 30 min followed by infusion rate (1X) of 0.0625 mcg/kg/hour for 5.5 hours).

DRUG

Placebo

6 hour IV infusion.

DRUG

Moxifloxacin

400 mg oral dose moxifloxacin within 1 min of start of infusion of exenatide

DRUG

Palonosetron

0.25 mg administered IV within 30 minutes prior to initiating the infusion of exenatide

Trial Locations (1)

Unknown

PRA-Groningen, Groningen

Sponsors
All Listed Sponsors
lead

Intarcia Therapeutics

INDUSTRY